Toni K Choueiri

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
  2. ncbi request reprint von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 180:860-5; discussion 865-6. 2008
  3. ncbi request reprint A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    T K Choueiri
    Dana Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston
    Ann Oncol 25:1603-8. 2014
  4. ncbi request reprint Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates
    Toni K Choueiri
    Toni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J Sweeney, Mary Ellen Taplin, Adam S Kibel, Katherine M Krajewski, Philip W Kantoff, Robert W Ross, and Jonathan E Rosenberg, Dana Farber Cancer Institute and Brigham and Women s Hospital Christopher Tretter, Lahey Clinic, Burlington Glenn J Bubley, Beth Israel Deaconess Medical Center, Boston, MA Leonard J Appleman, University of Pittsburgh, Pittsburgh, PA and Jonathan E Rosenberg, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:1889-94. 2014
  5. pmc Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
    G Sonpavde
    Urologic Medical Oncology, University of Alabama at Birmingham UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
    Br J Cancer 107:1009-16. 2012
  6. ncbi request reprint Clinical treatment decisions for advanced renal cell cancer
    Toni K Choueiri
    Kidney Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 11:694-7. 2013
  7. doi request reprint Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urol Oncol 30:848-55. 2012
  8. doi request reprint BRAF mutations in metanephric adenoma of the kidney
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur Urol 62:917-22. 2012
  9. pmc Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:507-12. 2012
  10. doi request reprint Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:1887-92. 2010

Detail Information

Publications94

  1. doi request reprint Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 26:127-31. 2008
    ..The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated...
  2. ncbi request reprint von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 180:860-5; discussion 865-6. 2008
    ..The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear...
  3. ncbi request reprint A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    T K Choueiri
    Dana Farber Cancer Institute and Harvard Medical School, Kidney Cancer Program, Boston
    Ann Oncol 25:1603-8. 2014
    ..Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC)...
  4. ncbi request reprint Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates
    Toni K Choueiri
    Toni K Choueiri, Susanna Jacobus, Joaquim Bellmunt, Angela Qu, Edward C Stack, Sabina Signoretti, Meghara Walsh, Graeme Steele, Michelle Hirsch, Christopher J Sweeney, Mary Ellen Taplin, Adam S Kibel, Katherine M Krajewski, Philip W Kantoff, Robert W Ross, and Jonathan E Rosenberg, Dana Farber Cancer Institute and Brigham and Women s Hospital Christopher Tretter, Lahey Clinic, Burlington Glenn J Bubley, Beth Israel Deaconess Medical Center, Boston, MA Leonard J Appleman, University of Pittsburgh, Pittsburgh, PA and Jonathan E Rosenberg, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 32:1889-94. 2014
    ..We explored the efficacy and safety of neoadjuvant ddMVAC with pegfilgrastim support in muscle-invasive urothelial cancer (MIUC)...
  5. pmc Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
    G Sonpavde
    Urologic Medical Oncology, University of Alabama at Birmingham UAB Comprehensive Cancer Center, Birmingham, AL 35294, USA
    Br J Cancer 107:1009-16. 2012
    ..Although biomarkers are in their infancy of development, they should be a priority in early preclinical and clinical development in order to guide rational tailored development of emerging agents...
  6. ncbi request reprint Clinical treatment decisions for advanced renal cell cancer
    Toni K Choueiri
    Kidney Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Natl Compr Canc Netw 11:694-7. 2013
    ..Increasingly, choice of therapy may be driven by toxicity profiles. Cytoreductive nephrectomy remains important, even in the era of targeted therapies in selected patients...
  7. doi request reprint Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urol Oncol 30:848-55. 2012
    ..To estimate costs for treatment of mRCC patients receiving angiogenesis inhibitors (AI) using resource utilization data from medical charts...
  8. doi request reprint BRAF mutations in metanephric adenoma of the kidney
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    Eur Urol 62:917-22. 2012
    ..Metanephric adenoma (MA) of the kidney is a rare, indolent tumor that may be difficult to differentiate from other small renal masses (SRMs). Genetic alterations associated with MA remain largely unknown...
  9. pmc Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 30:507-12. 2012
    ..Vandetanib in combination with docetaxel was assessed in patients with advanced urothelial cancer (UC) who progressed on prior platinum-based chemotherapy...
  10. doi request reprint Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:1887-92. 2010
    ..BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk..
  11. ncbi request reprint A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Genitourin Cancer 7:E93-4. 2009
    ....
  12. ncbi request reprint Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    BJU Int 105:1247-54. 2010
    ..To assess the effectiveness, safety, and treatment patterns of anti-angiogenic agents in metastatic renal cell carcinoma (mRCC) in tertiary clinical practice settings...
  13. doi request reprint The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy
    Toni K Choueiri
    Kidney Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 185:60-6. 2011
    ..Vascular endothelial growth factor targeted therapy is a standard of care in patients with metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of novel agents remains poorly defined...
  14. ncbi request reprint Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Dana Farber Harvard Cancer Center, Boston, MA, USA
    BJU Int 106:772-8. 2010
    ....
  15. ncbi request reprint VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective
    Toni K Choueiri
    Kidney Cancer Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Curr Clin Pharmacol 6:164-8. 2011
    ..The field is expanding rapidly with goals including 1) developing novel more potent and better tolerated agents and 2) defining the role of combination and sequential anti-VEGF regimens...
  16. doi request reprint Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urology 78:93-8. 2011
    ....
  17. doi request reprint Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    Cancer 116:5219-25. 2010
    ..In the current study, the authors investigated the effect of vascular endothelial growth factor (VEGF)-targeted therapy in this distinct subtype of RCC...
  18. doi request reprint Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, 44 Binney St Dana 1230, Boston, MA 02115, USA
    J Clin Oncol 28:2280-5. 2010
    ..We did a systematic review and meta-analysis to determine the incidence and the relative risk (RR) associated with the use of sunitinib and sorafenib...
  19. ncbi request reprint Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors
    Toni K Choueiri
    Harvard Medical School, Dana Farber Cancer Institute Brigham and Women s Hospital, Lank Center for Genitourinary Oncology, 44 Binney Street, Dana 1230, Boston, MA 02115, USA
    Curr Opin Investig Drugs 9:658-71. 2008
    ..Although frequent side effects have included fatigue, hypertension, diarrhea, hand-foot syndrome and proteinuria, axitinib was well tolerated overall. Larger, randomized phase II/III studies were ongoing at the time of publication...
  20. ncbi request reprint Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Havard Medical School, Boston, MA 02115, USA
    Clin Genitourin Cancer 6:15-20. 2008
    ..These models, if externally and prospectively validated, will rationally select patients for specific VEGF-directed therapeutic agents...
  21. pmc Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  22. ncbi request reprint A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy
    Toni K Choueiri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 179:906-10; discussion 910. 2008
    ..Imaging studies to document metastatic disease are frequently obtained but are often uninformative. In this study we identified clinical parameters that were predictive of positive imaging studies...
  23. ncbi request reprint Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer
    Arti Parekh
    Department of Radiation Oncology, Dana Farber Brigham and Women s Hospital, Harvard Medical School, Boston, MA
    Brachytherapy 12:415-21. 2013
    ..To determine which specific comorbidities predispose men to excess mortality by androgen deprivation therapy (ADT) given before and during brachytherapy for prostate cancer...
  24. doi request reprint Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 82:1411-6. 2012
    ....
  25. doi request reprint Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, Boston, MA, USA
    Eur Urol 59:856-62. 2011
    ..Since these therapies can induce tumor necrosis and minimal tumor shrinkage, Response Evaluation Criteria in Solid Tumors (RECIST) may not be optimal for predicting clinical outcome...
  26. doi request reprint Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors
    Fabio A B Schutz
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215 5415, USA
    J Clin Oncol 30:871-7. 2012
    ..We performed an up-to-date meta-analysis to determine the risk of fatal adverse events (FAEs) in patients with cancer treated with VEGFR TKIs...
  27. pmc Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group
    Judith Manola
    Eastern Cooperative Oncology Group Statistical Office, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Clin Cancer Res 17:5443-50. 2011
    ..To develop a single validated model for survival in metastatic renal cell carcinoma (mRCC) using a comprehensive international database...
  28. ncbi request reprint Weight gain on androgen deprivation therapy: which patients are at highest risk?
    Daniel M Seible
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Electronic address
    Urology 83:1316-21. 2014
    ..To identify factors associated with weight gain at 1 year from initiation of androgen deprivation therapy (ADT)...
  29. ncbi request reprint Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period
    Ayal A Aizer
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts
    Cancer 120:1532-9. 2014
    ..In the current study, the authors assessed whether racial disparities in cancer-specific mortality have improved over the last 20 years...
  30. doi request reprint Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis
    Sonia Seng
    Southcoast Centers for Cancer Care, Fairhaven, MA, USA
    J Clin Oncol 30:4416-26. 2012
    ....
  31. ncbi request reprint Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
    Youjin Je
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Lancet Oncol 10:967-74. 2009
    ..Bleeding has been described with these agents, although the overall risk remains unclear. We did a systematic review and meta-analysis to calculate the incidence and relative risk associated with use of sunitinib and sorafenib...
  32. doi request reprint Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone
    Arti Parekh
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Urology 81:130-4. 2013
    ..To report the relative incidence of the perceived reduction in penile size across prostate cancer treatment modalities and to describe its effect on quality of life and treatment regret...
  33. pmc Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer
    Rana R McKay
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02115, USA
    Drugs 73:1417-30. 2013
    ..Despite optimistic data, approval of neoadjuvant therapy prior to RP in patients with high-risk prostate cancer will depend on positive results from well designed phase III trials. ..
  34. doi request reprint Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma
    Aymen A Elfiky
    Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, MA 02115, USA
    Urol Oncol 29:756-63. 2011
    ..To identify factors that can be used to identify metastatic clear cell RCC patients more likely to benefit from sequential sunitinib...
  35. doi request reprint Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample
    Hua yin Yu
    Division of Urology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Eur Urol 61:1239-44. 2012
    ..Although robot-assisted laparoscopic radical cystectomy (RARC) was first reported in 2003 and has gained popularity, comparisons with open radical cystectomy (ORC) are limited to reports from high-volume referral centers...
  36. doi request reprint Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 79:1318-22. 2011
    ..Brachytherapy for prostate cancer can be technically challenging in men with small prostates (≤20 cc), but it is unknown whether their outcomes are different than those of men with larger prostates...
  37. doi request reprint Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis
    Tracy Proverbs-Singh
    Division of Hematology Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, Mount Sinai School of Medicine, 1 Gustave L Levy Pl, New York, NY 10029, USA
    J Natl Cancer Inst 104:1837-40. 2012
    ..67% (95% CI = 0.40% to 0.95%), and the RR of ATEs was 1.36 (95% CI = 0.86 to 2.17; P = .19). No increase in ATEs was detected in any prespecified subgroup...
  38. pmc Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
    ..Treatment of high-risk localized prostate cancer remains inadequate. The authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab before radical prostatectomy...
  39. pmc Cost implications of the rapid adoption of newer technologies for treating prostate cancer
    Paul L Nguyen
    Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    J Clin Oncol 29:1517-24. 2011
    ..We assessed temporal trends in their utilization and their impact on national health care spending...
  40. doi request reprint Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy
    Deborah A Ahove
    Smith College, Northhampton, Massachusetts, USA
    Urology 76:1201-5. 2010
    ..To determine the predictors of late prostate-specific antigen (PSA) failure among men with an undetectable PSA level 5 years after radical prostatectomy (RP)...
  41. ncbi request reprint Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)
    Toni K Choueiri
    Kidney Cancer Program, Dana Farber Harvard Cancer Center, Boston, MA 02215, USA Dana Farber Cancer Institute, Boston, MA 02215, USA Brigham and Women s Hospital, Boston, MA 02215, USA
    Urol Oncol 31:1788-93. 2013
    ..We examined the predictive value of CAIX in estimating treatment outcome in patients receiving sorafenib vs. placebo as part of the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET) study...
  42. ncbi request reprint Patterns of care for radical prostatectomy in the United States from 2003 to 2005
    Jim C Hu
    Division of Urologic Surgery, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 180:1969-74. 2008
    ..The demand for minimally invasive radical prostatectomy is increasing, although population based outcomes remain unclear. We assessed use and outcomes in American men undergoing radical prostatectomy...
  43. doi request reprint Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality
    Yolanda D Tseng
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Urol 187:2068-73. 2012
    ..We investigated whether the prostate specific antigen nadir predicts prostate cancer specific and all cause mortality in men treated in a randomized trial of radiation with or without 6 months of androgen deprivation therapy...
  44. pmc Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study
    Fabio A B Schutz
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 14:81-7. 2013
    ..Germline genetic polymorphisms might affect the risk of recurrence in patients with localised renal-cell carcinoma. We investigated the association between genetic polymorphisms and recurrence of renal-cell carcinoma...
  45. doi request reprint Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib
    Christopher J Richards
    Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 29:3450-6. 2011
    ..We performed an up-to-date meta-analysis to determine the risk of developing CHF in patients with both RCC and non-RCC tumors treated with sunitinib...
  46. doi request reprint Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 116:610-5. 2010
    ..Therefore, our ability to determine who would benefit from salvage hormonotherapy (HT) would be enhanced if an individual's risk of nonprostate-cancer-specific mortality were known...
  47. doi request reprint Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    JAMA 306:2359-66. 2011
    ....
  48. ncbi request reprint Marital status and survival in patients with cancer
    Ayal A Aizer
    Ayal A Aizer, Harvard Radiation Oncology Program Ellen P McCarthy, Beth Israel Deaconess Medical Center Mallika L Mendu, Sophia Koo, Powell L Graham, Neil E Martin, and Paul L Nguyen, Dana Farber Brigham and Women s Cancer Center Tyler J Wilhite, Harvard Medical School, Boston, MA Ming Hui Chen, University of Connecticut, Storrs, CT Karen E Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX and Jim C Hu, University of California at Los Angeles, Los Angeles, CA
    J Clin Oncol 31:3869-76. 2013
    ..To examine the impact of marital status on stage at diagnosis, use of definitive therapy, and cancer-specific mortality among each of the 10 leading causes of cancer-related death in the United States...
  49. doi request reprint Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis
    Mei Sheng Duh
    Analysis Group, Inc, Boston, MA 02199, USA
    Curr Med Res Opin 25:2081-90. 2009
    ..This study evaluated the incremental costs associated with IV administration of selected AI therapies (bevacizumab off-label) compared to oral therapies (sunitinib or sorafenib) for the treatment of RCC...
  50. ncbi request reprint Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, MA, USA
    Eur J Cancer 48:1495-502. 2012
    ..However, very few patients achieve response by response evaluation criteria in solid tumours (RECIST). Therefore, another 'response' threshold may be more useful than RECIST 1.0 in this setting...
  51. doi request reprint Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    Julia H Hayes
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    BJU Int 106:979-85. 2010
    ....
  52. doi request reprint Utilization and expense of adjuvant cancer therapies following radical prostatectomy
    Stephen B Williams
    Division of Urologic Surgery, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer 117:4846-54. 2011
    ..We sought to identify the costs of adjuvant therapies following radical prostatectomy (RP) and factors associated with their receipt...
  53. pmc Treatment selection for patients with metastatic renal cell carcinoma
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, MASCO Bldg, Room 412, 375 Longwood Avenue, Boston, MA 02115, USA
    Cancer 115:2327-33. 2009
    ....
  54. ncbi request reprint Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era
    Giorgio Gandaglia
    Giorgio Gandaglia, Pierre I Karakiewicz, and Maxine Sun, Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada Giorgio Gandaglia and Francesco Montorsi, Urological Research Institute, Vita Salute San Raffaele University, Milan, Italy Jesse D Sammon and Mani Menon, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI Steven L Chang, Toni K Choueiri, Adam S Kibel, Ramdev Konijeti, Paul L Nguyen, and Quoc Dien Trinh, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA Jim C Hu, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA Simon P Kim, Yale University, New Haven, CT and Shyam Sukumar, University of Minnesota, Minneapolis, MN
    J Clin Oncol 32:1419-26. 2014
    ....
  55. pmc Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC)
    Ayal A Aizer
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Boston, MA, USA
    BJU Int 113:E67-74. 2014
    ..To determine whether patients with metastatic non-clear-cell renal cell carcinoma (RCC) benefit from cytoreductive nephrectomy (CN)...
  56. doi request reprint Pazopanib versus sunitinib in metastatic renal-cell carcinoma
    Robert J Motzer
    Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    N Engl J Med 369:722-31. 2013
    ..This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy...
  57. pmc Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials
    Guru Sonpavde
    University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA
    Eur Urol 63:717-23. 2013
    ..The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) <10 g/dl, and liver metastasis (LM)...
  58. pmc Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
    Toni K Choueiri
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 31:181-6. 2013
    ..Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). We aimed to evaluate the efficacy and safety of foretinib in patients with PRCC...
  59. doi request reprint Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials
    Fabio A B Schutz
    Kidney Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Crit Rev Oncol Hematol 80:291-300. 2011
    ..We performed a meta-analysis to determine the incidence and risk of hematologic toxicities associated with sorafenib use...
  60. pmc Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors
    Emily S Robinson
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    Hypertension 56:1131-6. 2010
    ..Prospective studies are needed to explore whether these biomarkers may be useful predictors of efficacy in patients receiving VEGF-targeted therapies...
  61. doi request reprint Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men
    Jim C Hu
    Division of Urologic Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    Urology 77:402-6. 2011
    ..We characterized determinants of performance and extent of PLND during radical prostatectomy in elderly men...
  62. pmc 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute, and Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, and Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA Kidney Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 19:507-14. 2014
    ..Conclusion. Ten percent tumor shrinkage is validated as a reliable early predictor of outcome in mRCC patients receiving VEGF-targeted therapies and may provide a practical measure to guide therapeutic decisions. ..
  63. pmc Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria
    Katherine M Krajewski
    Department of Imaging, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts
    Cancer 120:711-21. 2014
    ..The objective of the current study was to determine intraobserver and interobserver agreement of computed tomography (CT) size and attenuation measurements to establish reproducible response indicators...
  64. doi request reprint Factors associated with the adoption of minimally invasive radical prostatectomy in the United States
    William D Ulmer
    Division of Urologic Surgery, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Urol 188:775-80. 2012
    ..We examined the influence of patient, surgeon and hospital characteristics on the use of minimally invasive radical prostatectomy vs radical retropubic prostatectomy...
  65. ncbi request reprint Targeted therapies: sunitinib in RCC-expanded access equals expanded benefit?
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Nat Rev Clin Oncol 6:679-80. 2009
    ..in an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice...
  66. ncbi request reprint Optimizing recent advances in metastatic renal cell carcinoma
    Kevin D Courtney
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Oncol Rep 11:218-26. 2009
    ....
  67. doi request reprint Congestive heart failure risk in patients with breast cancer treated with bevacizumab
    Toni K Choueiri
    Dana Farber Cancer Institute, 44 Binney St Dana 1230, Boston MA 02115, USA
    J Clin Oncol 29:632-8. 2011
    ..We performed an up-to-date, comprehensive meta-analysis to determine the risk of serious CHF in patients with breast cancer receiving bevacizumab...
  68. pmc The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
    Fabio A B Schutz
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Eur Urol 65:723-30. 2014
    ..Hyponatremia has been associated with poor survival in many solid tumors and more recently found to be of prognostic and predictive value in metastatic renal cell cancer (mRCC) patients treated with immunotherapy...
  69. ncbi request reprint Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome
    Donnette A Dabydeen
    Dana Farber Cancer Institute Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, United States
    Eur J Cancer 48:1519-24. 2012
    ..Correlation between radiological findings of pneumonitis and clinical outcome was also determined...
  70. doi request reprint Haematologic toxicities associated with the addition of bevacizumab in cancer patients
    Fabio A B Schutz
    Kidney Cancer Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 47:1161-74. 2011
    ..We performed a meta-analysis to determine the incidence and risk of haematologic toxicities associated with bevacizumab...
  71. pmc Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives
    Steven M Bair
    Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women s Hospital, MA 02115, USA
    Trends Cardiovasc Med 23:104-13. 2013
    ....
  72. pmc ABO blood group and risk of renal cell cancer
    Hee Kyung Joh
    Department of Nutrition, Harvard School of Public Health, Boston, MA, USA
    Cancer Epidemiol 36:528-32. 2012
    ..Previous studies have suggested associations between ABO blood group and risk of various cancers. However, its relationship to RCC remains unclear and no prospective data are available...
  73. doi request reprint Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid
    Fabio A B Schutz
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Expert Opin Drug Saf 10:645-53. 2011
    ..Therefore, the development of new agents with improved efficacy is warranted. Recently, a new synthetic vinca alkaloid, vinflunine, was developed through the addition of two fluor molecules by superacidic chemistry...
  74. pmc Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts
    Wei Liu
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 118:797-803. 2012
    ..Statins are widely used cholesterol-lowering agents that may have potential antitumor effect. Epidemiological studies on statin use and renal cell carcinoma (RCC) risk have been inconsistent...
  75. ncbi request reprint New therapies for castrate-resistant prostate cancer
    Stephen B Williams
    Division of Urology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Expert Opin Pharmacother 12:2069-74. 2011
    ..There has been better understanding of castration resistance and molecular mechanisms of prostate cancer progression recently, leading to new treatment strategies...
  76. doi request reprint Pazopanib: Clinical development of a potent anti-angiogenic drug
    Fabio A B Schutz
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Crit Rev Oncol Hematol 77:163-71. 2011
    ..In metastatic breast cancer, the combination of pazopanib with lapatinib was more effective than lapatinib alone. At the time of the current publication, pazopanib is being evaluated in more than 35 phase II and III trials...
  77. ncbi request reprint Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties
    Toni K Choueiri
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MS, USA
    Nat Clin Pract Oncol 5:444-54. 2008
    ....
  78. pmc Prospective evaluation of analgesic use and risk of renal cell cancer
    Eunyoung Cho
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Arch Intern Med 171:1487-93. 2011
    ..Epidemiologic data suggest that analgesic use increases the risk of renal cell cancer (RCC), but few prospective studies have been published. We investigated the association between analgesic use and RCC in 2 large prospective studies...
  79. ncbi request reprint An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications
    Toni K Choueiri
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    BJU Int 101:712-5. 2008
    ..To describe an association between renal cell carcinoma (RCC) and multiple myeloma (MM) in patients with both disorders, and suggest possible explanations for the association...
  80. pmc Updates on novel therapies for metastatic renal cell carcinoma
    Kevin D Courtney
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Ther Adv Med Oncol 2:209-19. 2010
    ....
  81. ncbi request reprint The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma
    Toni K Choueiri
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    Semin Oncol 33:596-606. 2006
    ..This review will describe the current clinical data with VEGF-targeted approaches in RCC and plans for future development...
  82. ncbi request reprint Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics
    Snehal G Thakkar
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R 35, Cleveland, OH 44195, USA
    Curr Oncol Rep 8:108-13. 2006
    ....
  83. ncbi request reprint Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941
    Bernard Escudier
    Institut Gustave Roussy, Villejuif, France
    J Urol 178:1901-5. 2007
    ..We analyzed prognostic factors, described survival and generated a prognostic model in patients with metastatic renal cell carcinoma in whom immunotherapy failed and who were potentially eligible for novel agents...
  84. ncbi request reprint Phase II study of lenalidomide in patients with metastatic renal cell carcinoma
    Toni K Choueiri
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Cancer 107:2609-16. 2006
    ..A Phase II, open-label study of LEN in patients with metastatic renal cell carcinoma (RCC) was conducted to determine its safety and clinical activity...
  85. ncbi request reprint Management of clinical stage I nonseminomatous germ cell testicular cancer
    Toni K Choueiri
    Department of Solid Tumor Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195 0001, USA
    Urol Clin North Am 34:137-48; abstract viii. 2007
    ..For patients at high risk for relapse and who are not candidates for surveillance, we believe the evidence supports RPLND over primary chemotherapy...
  86. ncbi request reprint Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    Toni K Choueiri
    Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, USA
    Cancer 110:543-50. 2007
    ..The identification of patients who are more likely to benefit from these agents is warranted...
  87. ncbi request reprint Differential expression of caveolin-1 in renal neoplasms
    Ila Tamaskar
    Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA
    Cancer 110:776-82. 2007
    ..In the current study, the authors used immunohistochemistry to investigate the membranous and cytoplasmic expression of caveolin-1 and its correlation with other pathologic parameters in different subtypes of renal neoplasms...
  88. ncbi request reprint Evolving role of pegylated interferons in metastatic renal cell carcinoma
    Toni K Choueiri
    Department of Internal Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Expert Rev Anticancer Ther 3:823-9. 2003
    ..Studies evaluating these agents in the treatment of metastatic renal cell carcinoma and other cancers are ongoing...
  89. doi request reprint Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies
    Ali Reza Golshayan
    Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, R 35, Cleveland, OH 44195, USA
    Future Oncol 4:85-92. 2008
    ..These models, if externally and prospectively validated, will culminate in the rational selection of patients for specific VEGF-directed therapeutics...
  90. doi request reprint Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA
    Cancer 113:1309-14. 2008
    ..Cytopenia and macrocytosis have been described in patients treated with these agents...
  91. ncbi request reprint Phenoxodiol: isoflavone analog with antineoplastic activity
    Toni K Choueiri
    Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R 35, Cleveland, OH 44195, USA
    Curr Oncol Rep 8:104-7. 2006
    ..Hormone-refractory prostate cancer is another promising area in which phenoxodiol is being actively tested. Studies are ongoing to define the optimal use of this novel anticancer agent...
  92. ncbi request reprint The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma
    Rony M Abou-Jawde
    Myeloma Research Program, Cleveland Clinic, Cleveland, Ohio, USA
    Haematologica 91:1410-3. 2006
    ..In conclusion, socioeconomic status, distance traveled and race did not affect outcomes of MM patients treated at a specialized myeloma center...
  93. ncbi request reprint The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study
    Sarah M Short
    Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
    Breast J 13:130-9. 2007
    ..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...
  94. ncbi request reprint Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia
    Jennifer K Long
    Department of Pharmacy, Clinical Microbiology Section, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Mayo Clin Proc 80:1215-6. 2005
    ..No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives...